Astellas Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Naoki Okamura
- Full Time Employees
- 14,754
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2-5-1, Nihonbashi-Honcho Tokyo Japan 103-8411
- IPO Date
- Apr 26, 2010
- Website
- astellas.com
- Similar Companies
- Business
- Astellas Pharma Inc. operates as a prominent global pharmaceutical enterprise, engaging in the worldwide development, production, marketing, and distribution of advanced medicinal products. The organization is committed to translating innovative scientific insights into meaningful patient value, with a strong emphasis on pioneering solutions for diseases characterized by high unmet medical requirements. Its comprehensive portfolio of commercially available treatments features XTANDI, a critical androgen receptor signaling inhibitor for prostate cancer; PADCEV, approved for adult patients with locally advanced or metastatic urothelial cancer; and XOSPATA, a FLT3 inhibitor targeting adult individuals with relapsed or refractory acute myeloid leukemia presenting a FLT3 mutation. Astellas additionally offers IZERVAY, a therapy for geographic atrophy, integrated through a recent strategic acquisition, and Betanis/Myrbetriq/BETMIGA, used in the management of overactive bladder. Other key pharmaceutical assets include Evrenzo, an oral treatment for anemia associated with chronic kidney disease, and the immunosuppressive agents Prograf and Advagraf/Graceptor/ASTAGRAF, crucial for mitigating organ rejection following transplantation. Recent product advancements also include VYLOY for gastric and gastroesophageal junction cancers. The company directs its research and development initiatives through a distinct "Focus Area Approach," prioritizing cutting-edge biology and novel therapeutic modalities. Core R&D areas include Blindness and Regeneration, Genetic Regulation, Immuno-Oncology, and Targeted Protein Degradation, demonstrating a dedication to developing future-oriented healthcare innovations. The development pipeline encompasses drug candidates for conditions such as urothelial cancer, gastric cancer, and acute myeloid leukemia. To further its strategic goals, Astellas actively pursues significant collaborations and acquisitions. Noteworthy recent activities include the 2023 acquisition of IVERIC Bio for $5.9 billion, which expanded its ophthalmology offerings with IZERVAY, and the purchase of Propella Therapeutics for $175 million, adding PRL-02 for prostate cancer to its oncology suite. The company maintains a key clinical trial partnership with Merck concerning treatments such as PADCEV combined with Keytruda for bladder cancer. Additional alliances include a strategic collaboration initiated in January 2024 with Mass General Brigham, focused on advancing translational medicine in oncology, rare disease, and cell and gene therapies. Astellas also collaborates with Sutro Biopharma on antibody-drug conjugate technologies and Dyno Therapeutics for next-generation gene therapy vectors, among numerous other research agreements designed to harness external innovation. Established in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas Pharma Inc. maintains its headquarters in Tokyo, Japan, and conducts operations across more than 70 countries globally. The company exhibits robust financial performance, with global revenue in fiscal year 2024 reaching ¥1,912.3 Billion, supported by an investment of 17.1% of its sales revenue into research and development programs.
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Completes Acquisition of Iveric Bio
You can't rely on indexes to pick international stocks, this 5-star fund manager says. Here are 3 of his top selections.
Iveric Bio stock surges on Astellas Pharma takeover deal
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion